Amarantus Provides Corporate Update NEW YORK, July 20,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
155
Amarantus Provides Corporate Update

NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today provided a business update on each of its subsidiaries Elto Pharma, Inc., Cutanogen Corporation, NeuroDx (pending formation to develop LymPro Test) and MANF Therapeutics, Inc. In addition, the Company provided guidance on its funding plan to complete its recapitalization and initiate its subsidiary spinoff plan.

Elto Pharma

The Elto Pharma project team (Drs. Trzepacz, Harvey and Brownell) has been focused on revising the Phase 2b eltoprazine clinical trial design and has now established a revised synopsis for a parallel design, Phase 2b Parkinson's disease levodopa-induced dyskinesia (PD-LID) trial that takes into account changes in the standard of care being made as a result of the recent approval of Adamas' Gocovri. The team is currently engaging with experts in the field ahead of regulatory interactions and expects to initiate the trial in the first half of 2019.

In addition, there has been a renewed focus on evaluating a potential secondary indication for eltoprazine that is related to Alzheimer's disease. The team has made substantial progress, in consultation with our Alzheimer's SAB, in refining the target product profile for eltoprazine in that area. Further information on our plans in this area will be provided in the second half of 2018.

Cutanogen

The Cutanogen project team (Drs. Kagan, Ahrenholz, Harvey and Brownell) has been focused on defining the fastest path to market for Engineered Skin Substitute (ESS) in pediatric severe burns, and preparing to re-establish the ESS manufacturing process at a third-party cell therapy contract manufacturer. To this end, Cutanogen recently engaged with a new world-renowned cell therapy contract manufacturing organization (CMO) to assess and provide a roadmap to optimize the ESS manufacturing process in preparation for clinical trials expected to initiate in the first half of 2019. This effort will provide guidance on strategies to accelerate time to patient, reduce costs of good sold (COGS) and prepare to scale volume to meet the commercial needs. The Company expects to finalize its regulatory strategy in pediatric burns in the second half of 2018 and initiate interaction with relevant regulatory agencies to guide planning for ESS' path to market.

MANF Therapeutics

In the first half of 2018, MANF Therapeutics announced the issuance of several patents and independent peer-reviewed publications related to MANF in the areas of Glaucoma, Parkinson's disease, diabetes and Wolfram's disease, as well as TBI and stroke. The next major steps for the MANF program revolve around re-initiating cGMP manufacturing, selection of the indication for first-in-man studies and completing the recruiting process with senior executive-level talent. MANF Therapeutics owns protein therapy and gene therapy rights to MANF, including patents and patent applications in the areas of ophthalmology, neurology and metabolism.

NeuroDx

In May 2018, Amarantus exercised its exclusive option with Leipzig University to license additional intellectual property rights to its LymPro Test generated from a recently completed German clinical trial designed to assess the LymPro vs. amyloid PET imaging. Amarantus is currently finalizing the transaction and will form the legal entity to house the development of the LymPro Test shortly.

Dr. Ropacki, the LymPro Test Chief Medical Advisor, will be attending the upcoming Alzheimer's Association International Conference (AAIC) in Chicago, IL, and will be re-engaging with key stakeholders in the area of Alzheimer's diagnostics on behalf of Amarantus.

AMBS Capital Formation Plan

In March 2018, the Company announced the participation of 96%+ of its legacy convertible debt (LCD) holders in the Tender Exchange, which reduced overall balances, removed ratchet provisions, provided a 9-month moratorium on conversions, and provided a path to releasing all outstanding liens and retiring the LCD securities. In the first quarter of 2018, the Company also entered into agreements to raise up to $1.5 million in funding to begin executing on the restructuring path created via the Tender Exchange. In the second quarter of 2018, Amarantus retained Weild & Co. to advise it on capital formation via the JOBS Act.

After a thorough review, the Company has concluded that the parent Company's best strategy is to file a Regulation A offering in preparation for an eventual equity raise to fund AMBS going forward. The Company maintains the right for its subsidiaries to raise capital, which would have the effect of releasing liens on an individual subsidiary basis. The Company can also achieve its objectives via the issuance of long-term debt, or certain other restricted securities. In parallel with this, the Company is finalizing the plans for Elto Pharma and Cutanogen that it believes will drive near-term value as those subsidiaries prepare to re-enter clinical development.

The Company has engaged its auditors to initiate a review of its 2016, 2017 and first half of 2018 financials, which sets the stage for a full audit to allow the Company to becoming fully reporting. Recently-passed legislation allows fully-reporting companies to utilize the Regulation A funding mechanism to raise capital.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor will there be any offer, solicitation or sale of securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction.

About Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc . has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program, a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation . AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders and Parkinson's disease. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. The Company also owns certain rights to the Alzheimer's blood diagnostic LymPro Test , as well as MSPrecise and NuroPro.

For further information please visit www.Amarantus.com , or connect with the Amarantus on Facebook , LinkedIn , Twitter  and Google+ .

Amarantus Investor and Media Contact:

Howard Gostfrand

American Capital Ventures, Inc.

Office: 305-918-7000

Email: hg@amcapventures.com

Source: Amarantus Bioscience Holdings, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 124

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 7

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

VOOG's 15-Year Climb: Compounding Gains or Just a Mirage?

Updated Category News Views 255

Fifteen years back, you could have dropped $1000 into the Vanguard S&P 500 Growth ETF (NYSE:VOOG), and that cash would’ve exploded into a whopping $7,164.65 today. That’s a staggering annualized return of 14.01%, comfortably outpacing the market by about 2.35%. Sounds easy, right? But let’s peel back this seemingly golden curtain. VOOG's Performance: The Big Picture...

Continue Reading
Mercer International Inc. Faces Financial Challenges in Q2 2025

Updated Category News Views 256

Financial Overview of Mercer International Inc. for Q2 2025 Mercer International Inc. recently disclosed its financial performance for the second quarter of 2025, revealing significant challenges. The company reported an Operating EBITDA of negative $20.9 million alongside a net loss of $86.1 million, a stark contrast to the positive $30.4 million Operating EBITDA and a...

Continue Reading
EU's Strategic Response to Potential Trade Challenges with Trump

Updated Category News Views 167

EU's Trade Engagement Strategy with the New Administration The European Union is gearing up for an essential phase in its trade relations with the U.S. as Donald Trump prepares to take office once again. The EU's ministers have clearly expressed the need to foster constructive dialogue regarding trade policies while remaining vigilant about any potential tariff...

Continue Reading
Regenative Labs Casts Spotlight on Plantar Fascia Innovations

Updated Category News Views 44

Rethinking Plantar Fasciitis with Wharton’s Jelly When it comes to those of us keeping an eye on regenerative medicine, it’s like standing on the edge of a wild frontier sometimes. Today, we’ve got Regenative Labs out of Pensacola shining a light on something that’s often a real pain—literally and figuratively: plantar fasciitis. Clinical Studies with Promising...

Continue Reading
GC Biopharma's BARYCELA Secures Marketing Authorization

Updated Category News Views 171

GC Biopharma's Breakthrough with BARYCELA GC Biopharma, a prominent South Korean pharmaceutical company, has achieved a significant milestone with the recent marketing authorization of its varicella vaccine, BARYCELA, in Vietnam. This accomplishment follows earlier domestic approval and WHO Pre-Qualification, demonstrating the company’s commitment to expanding its...

Continue Reading